دورية أكاديمية
Histone demethylase PHF8 promotes prostate cancer metastasis via the E2F1-SNAI1 axis.
| العنوان: | Histone demethylase PHF8 promotes prostate cancer metastasis via the E2F1-SNAI1 axis. |
|---|---|
| المؤلفون: | Wang Z; Department of Urology, Daping Hospital, Army Medical University, Chongqing, PR China., Tang P; Department of Urology, Daping Hospital, Army Medical University, Chongqing, PR China., Xiao H; Department of Urology, Daping Hospital, Army Medical University, Chongqing, PR China., Peng S; Department of Urology, Daping Hospital, Army Medical University, Chongqing, PR China., Chen J; Department of Urology, Daping Hospital, Army Medical University, Chongqing, PR China., Wang Y; Department of Urology, Daping Hospital, Army Medical University, Chongqing, PR China., Xu J; Department of Urology, Daping Hospital, Army Medical University, Chongqing, PR China., Yan Q; Department of Urology, Daping Hospital, Army Medical University, Chongqing, PR China., Zhang J; Chongqing Key Laboratory of High Active Traditional Chinese Drug Delivery System, Chongqing Engineering Research Center of Pharmaceutical Sciences, Chongqing Medical and Pharmaceutical College, Chongqing, PR China.; College of Pharmacy, Chongqing Medical University, Chongqing, PR China., Deng J; Department of Urology, Daping Hospital, Army Medical University, Chongqing, PR China., Ma Q; Department of Urology, Daping Hospital, Army Medical University, Chongqing, PR China., Zhu H; Department of Urology, Daping Hospital, Army Medical University, Chongqing, PR China., Luo W; Department of Urology, Daping Hospital, Army Medical University, Chongqing, PR China., Zhang D; Department of Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine, Philadelphia, PA, USA., Wang L; Department of Urology, Daping Hospital, Army Medical University, Chongqing, PR China., Qin J; CAS Key Laboratory of Tissue Microenvironment and Tumor, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Nutrition and Health Sciences, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, PR China., Lan W; Department of Urology, Daping Hospital, Army Medical University, Chongqing, PR China., Jiang J; Department of Urology, Daping Hospital, Army Medical University, Chongqing, PR China., Liu Q; Department of Urology, Daping Hospital, Army Medical University, Chongqing, PR China. |
| المصدر: | The Journal of pathology [J Pathol] 2024 Jul 18. Date of Electronic Publication: 2024 Jul 18. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: John Wiley And Sons Country of Publication: England NLM ID: 0204634 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-9896 (Electronic) Linking ISSN: 00223417 NLM ISO Abbreviation: J Pathol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Chichester : John Wiley And Sons Original Publication: London, Oliver & Boyd. |
| مستخلص: | Metastasis is the primary culprit behind cancer-related fatalities in multiple cancer types, including prostate cancer. Despite great advances, the precise mechanisms underlying prostate cancer metastasis are far from complete. By using a transgenic mouse prostate cancer model (TRAMP) with and without Phf8 knockout, we have identified a crucial role of PHF8 in prostate cancer metastasis. By complexing with E2F1, PHF8 transcriptionally upregulates SNAI1 in a demethylation-dependent manner. The upregulated SNAI1 subsequently enhances epithelial-to-mesenchymal transition (EMT) and metastasis. Given the role of the abnormally activated PHF8/E2F1-SNAI1 axis in prostate cancer metastasis and poor prognosis, the levels of PHF8 or the activity of this axis could serve as biomarkers for prostate cancer metastasis. Moreover, targeting this axis could become a potential therapeutic strategy for prostate cancer treatment. © 2024 The Pathological Society of Great Britain and Ireland. (© 2024 The Pathological Society of Great Britain and Ireland.) |
| References: | Bubendorf L, Schöpfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000; 31: 578–583. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7–30. Sena LA, Denmeade SR. Fatty acid synthesis in prostate cancer: vulnerability or epiphenomenon? Cancer Res 2021; 81: 4385–4393. Manzar N, Ganguly P, Khan UK, et al. Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer. Semin Cancer Biol 2023; 89: 76–91. Mughees M, Kaushal JB, Sharma G, et al. Chemokines and cytokines: axis and allies in prostate cancer pathogenesis. Semin Cancer Biol 2022; 86: 497–512. Sartor O, deBono JS. Metastatic prostate cancer. N Engl J Med 2018; 378: 645–657. Zhang Y, Zhao J, Ding M, et al. Loss of exosomal miR‐146a‐5p from cancer‐associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis. J Exp Clin Cancer Res 2020; 39: 282. Cheng C, Ji Z, Sheng Y, et al. Aphthous ulcer drug inhibits prostate tumor metastasis by targeting IKKɛ/TBK1/NF‐κB signaling. Theranostics 2018; 8: 4633–4648. Bourcy M, Suarez‐Carmona M, Lambert J, et al. Tissue factor induced by epithelial‐mesenchymal transition triggers a procoagulant state that drives metastasis of circulating tumor cells. Cancer Res 2016; 76: 4270–4282. Li P, Yang R, Gao WQ. Contributions of epithelial‐mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. Mol Cancer 2014; 13: 55. Wang Q, Ma S, Song N, et al. Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis. J Clin Invest 2016; 126: 2205–2220. Björkman M, Östling P, Härmä V, et al. Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion. Oncogene 2012; 31: 3444–3456. Shen Y, Pan X, Zhao H. The histone demethylase PHF8 is an oncogenic protein in human non‐small cell lung cancer. Biochem Biophys Res Commun 2014; 451: 119–125. Peng S, Wang Z, Tang P, et al. PHF8‐GLUL axis in lipid deposition and tumor growth of clear cell renal cell carcinoma. Sci Adv 2023; 9: eadf3566. Liu Q, Pang J, Wang LA, et al. Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2. J Pathol 2021; 253: 106–118. Cui J, Zhang C, Lee JE, et al. MLL3 loss drives metastasis by promoting a hybrid epithelial‐mesenchymal transition state. Nat Cell Biol 2023; 25: 145–158. Pillai S, Trevino J, Rawal B, et al. β‐arrestin‐1 mediates nicotine‐induced metastasis through E2F1 target genes that modulate epithelial‐mesenchymal transition. Cancer Res 2015; 75: 1009–1020. Liu Q, Tong D, Liu G, et al. Metformin inhibits prostate cancer progression by targeting tumor‐associated inflammatory infiltration. Clin Cancer Res 2018; 24: 5622–5634. Rosenbaum E, Partin A, Eisenberger MA. Biochemical relapse after primary treatment for prostate cancer: studies on natural history and therapeutic considerations. J Natl Compr Canc Netw 2004; 2: 249–256. Hua Q, Zhu Y, Liu H, et al. Diabetes and the risk of biochemical recurrence in patients with treated localized prostate cancer: a meta‐analysis. Int Urol Nephrol 2016; 48: 1437–1443. Li N, Liu Q, Han Y, et al. ARID1A loss induces polymorphonuclear myeloid‐derived suppressor cell chemotaxis and promotes prostate cancer progression. Nat Commun 2022; 13: 7281. Wang H, Li N, Liu Q, et al. Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. Cancer Cell 2023; 41: 1345–1362.e9. Abate‐Shen C. Prostate cancer metastasis – fueled by fat? N Engl J Med 2018; 378: 1643–1645. Martens‐Uzunova ES, Böttcher R, Croce CM, et al. Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol 2014; 65: 1140–1151. Shafran JS, Jafari N, Casey AN, et al. BRD4 regulates key transcription factors that drive epithelial‐mesenchymal transition in castration‐resistant prostate cancer. Prostate Cancer Prostatic Dis 2021; 24: 268–277. Yuan H, Han Y, Wang X, et al. SETD2 restricts prostate cancer metastasis by integrating EZH2 and AMPK signaling pathways. Cancer Cell 2020; 38: 350–365.e357. Feng R, Li Z, Ge G, et al. NEDD4L represses prostate cancer cell proliferation via modulating PHF8 through the ubiquitin‐proteasome pathway. Clin Transl Oncol 2023; 25: 243–255. Maina PK, Shao P, Liu Q, et al. c‐MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration‐resistant prostate cancer. Oncotarget 2016; 7: 75585–75602. Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol 2022; 15: 129. Brabletz T, Jung A, Spaderna S, et al. Opinion: migrating cancer stem cells – an integrated concept of malignant tumour progression. Nat Rev Cancer 2005; 5: 744–749. Debaugnies M, Rodríguez‐Acebes S, Blondeau J, et al. RHOJ controls EMT‐associated resistance to chemotherapy. Nature 2023; 616: 168–175. Miao L, Yang L, Li R, et al. Disrupting androgen receptor signaling induces snail‐mediated epithelial‐mesenchymal plasticity in prostate cancer. Cancer Res 2017; 77: 3101–3112. Mak P, Leav I, Pursell B, et al. ERbeta impedes prostate cancer EMT by destabilizing HIF‐1alpha and inhibiting VEGF‐mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 2010; 17: 319–332. van denHeuvel S, Dyson NJ. Conserved functions of the pRB and E2F families. Nat Rev Mol Cell Biol 2008; 9: 713–724. Peng YP, Zhu Y, Yin LD, et al. PEG10 overexpression induced by E2F‐1 promotes cell proliferation, migration, and invasion in pancreatic cancer. J Exp Clin Cancer Res 2017; 36: 30. Gingrich JR, Barrios RJ, Morton RA, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996; 56: 4096–4102. Beltran H, Prandi D, Mosquera JM, et al. Divergent clonal evolution of castration‐resistant neuroendocrine prostate cancer. Nat Med 2016; 22: 298–305. Soundararajan R, Paranjape AN, Maity S, et al. EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers. Biochim Biophys Acta Rev Cancer 2018; 1870: 229–238. McKeithen D, Graham T, Chung LW, et al. Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells. Prostate 2010; 70: 982–992. Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration‐resistant prostate cancer. Nature 2012; 487: 239–243. |
| معلومات مُعتمدة: | 82372758 National Natural Science Foundation of China; 81802558 National Natural Science Foundation of China; 2018XLC1014 University Research Project of Army Medical University; 2019CXLCB006 University Research Project of Army Medical University; 2021XQN24 University Research Project of Army Medical University |
| فهرسة مساهمة: | Keywords: E2F1; EMT; PHF8; SNAI1; metastasis; prostate cancer |
| تواريخ الأحداث: | Date Created: 20240718 Latest Revision: 20240718 |
| رمز التحديث: | 20240718 |
| DOI: | 10.1002/path.6325 |
| PMID: | 39022843 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1096-9896 |
|---|---|
| DOI: | 10.1002/path.6325 |